Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease

European Respiratory Journal

Volumn 21, Issue 1, 2003, Pages 74-81

  Szafranski, W ^a   Cukier, A ^b   Ramirez, A ^c   Menga, G ^d   Sansores, R ^e   Nahabedian, S ^f   Peterson, S ^g   Olsson, Hakan ^g  

^a Voivodeship Specialist Hospital   (Poland)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c Hospital Enfermedades Cardiovasculares y Torax   (Mexico)

^d Section Endoscopy   (Argentina)

^e INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

^f Evita Hospital   (Argentina)

^g ASTRAZENECA R AND D   (Sweden)

Author keywords

Budesonide; Budesonide formoterol; Chronic obstructive pulmonary disease; Exacerbations; Formoterol

Indexed keywords

ANTIBIOTIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID DERIVATIVE; FLUTICASONE; FORMOTEROL; PLACEBO; SALBUTAMOL; SALMETEROL; STEROID; TERBUTALINE; XANTHINE DERIVATIVE;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXPIRATORY FLOW RATE; FORCED EXPIRATORY VOLUME; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; METERED DOSE INHALER; MULTICENTER STUDY; PARALLEL DESIGN; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SYMPTOMATOLOGY;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; BUDESONIDE; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; ETHANOLAMINES; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; PEAK EXPIRATORY FLOW RATE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TIME FACTORS;

EID: 0037246566     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.03.00031402     Document Type: Article

References (34)

1. World health report. Geneva: World Health Organization, 2000. http://www.who.int/whr/2000/en/statistics.htm. Date last updated: continuous.
2. GOLD: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHI publication no. 2701, March 2001.
3. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 1418-1422.
4. Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1 The Lung Health Study. JAMA 1994; 272: 1497-1505.
5. Scanlon PD, Connett JE, Waller LA, Altose MD, Bailey WC, Buist AS. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. Am J Respir Crit Care Med 2000; 161: 381-390.
6. Turato G, Di Stefano A, Maestrelli P, et al. Effect of smoking cessation on airway inflammation in chronic bronchitis. Am J Respir Crit Care Med 1995; 152: 1262-1267.
7. Rutgers SR, Postma DS, Hacken NH, et al. Ongoing airway inflammation in patients with COPD who do not currently smoke. Thorax 2000; 55: 12-18.
8. 2-agonists in the management of stable chronic obstructive pulmonary disease. Drugs 2000; 60: 307-320.
9. Boyd G, Morice AH, Pounsford JC, Siebert M, Peslis N, Crawford C. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD). Eur Respir J 1997; 10: 815-821.
10. Wadbo M, Löfdahl CG, Larsson K, et al. A placebo-controlled comparison of the effects of formoterol and ipratropium bromide in patients with COPD. Eur Respir J 1999; 14: Suppl. 30, 381s.
11. Jones PW, Bosch TK. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med 1997; 155: 1283-1289.
12. Greefhorst APM, Dahl R, Nowak D, et al. for the FICOPD I study group. Effect of inhaled formoterol and ipratropium bromide on quality of life, "bad days" and exacerbations in patients with COPD. Am J Respir Crit Care Med 2000; 161: A490.
13. Çelik G, Kayacan O, Beder S, Durmaz G. Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: A crossover, placebo-controlled comparison of onset and duration of action. Respiration 1999; 66: 434-439.
14. Cazzola M, Centanni S, Regorda C, et al. Onset of action of single doses of formoterol administered via Turbuhaler in patients with stable COPD. Pulm Pharmacol Ther 2001; 14: 41-45.
15. Paggiaro PL, Dahl R, Bakran I, Frith L, Hollingworth K, Efthimiou J. Multicentre, randomized placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. Lancet 1998; 351: 773-780.
16. Jarad NA, Wedzicha JA, Burge PS, Calverley PMA, for the ISOLDE study group. An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. Respir Med 1999; 93: 161-166.
17. Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000; 343: 1902-1909.
18. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomized, double-blind, placebo-controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320: 1297-1303.
19. Sin DD, Tu JV. Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 580-584.
20. Korn SH, Jerre A, Brattsand R. Effects of formoterol and budesonide on GM-CSF and IL-8 secretion by triggered human bronchial epithelial cells. Eur Respir J 2001; 17: 1059-1061.
21. Spoelstra FM, Postma DS, Hovenga H, Noordhoek JA, Kauffman HF. Additive anti-flammatory effect of formoterol and budesonide on human lung fibroblasts. Thorax 2002; 57: 237-241.
22. Pauwels RA, Lofdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997; 337: 1405-1411.
23. 2-agonists and corticosteroids. Eur Respir J 2002; 19: 182-191.
24. Jones PW, Quirk FH, Baveystock CM. The St George's Respiratory Questionnaire. Respir Med 1991; 85: Suppl. 16, 25-31.
25. CPMP Guidelines: Points to consider on clinical investigation of medicinal products in the chronic treatment of patients with chronic obstructive pulmonary disease (COPD). London, 19 May 1999 CPMP/EWP/562/98.
26. Seemungal TA, Harper-Own R, Bhowmik A, et al. Respiratory viruses, symptoms and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 1618-1623.
27. Cazzola M, Matera MG, Santangelo G, Vinciguerra A, Rossi F, DAmato G. Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study. Respir Med 1995; 89: 357-362.
28. Aalbers R, Ayres J, Backer V, et al. Formoterol in patients with chronic obstructive pulmonary disease, a randomised, controlled, 3-month trial. Eur Respir J 2002; 19: 936-943.
29. Redelmeier DA, Goldstein RS, Min ST, Hyland RH. Spirometry and dyspnea with COPD. When small differences mean little. Chest 1996; 109: 1163-1168.
30. Pauwels RA, Löfdahl C-G, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N Engl J Med 1999; 340: 1948-1953.
31. Johnell O, Pauwels R, Löfdahl C-G, et al. Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler®. Eur Respir J 2002; 19: 1058-1063.
32. Dahl R, Kristufek P, Greefhorst APM, Amgott TR, Della Cioppa G, Thomson MH. The cardiac safety profile of formoterol dry powder is similar to placebo in patients with COPD. Eur Respir J 2000; 16: Suppl. 31, 51s.
33. Pauwels RA, Löfdahl C-G, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997; 337: 1405-1411.
34. O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma. Am J Respir Crit Care Med 2001; 164: 1392-1397.